2024-03-29T00:57:56Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_C26272A946F7
2024-03-23T02:56:24Z
serval:BIB_C26272A946F7
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
10.1016/S1470-2045(15)00208-9
26538423
000365803700060
Stahel
R.A.
author
Riesterer
O.
author
Xyrafas
A.
author
Opitz
I.
author
Beyeler
M.
author
Ochsenbein
A.
author
Früh
M.
author
Cathomas
R.
author
Nackaerts
K.
author
Peters
S.
author
Mamot
C.
author
Zippelius
A.
author
Mordasini
C.
author
Caspar
C.B.
author
Eckhardt
K.
author
Schmid
R.A.
author
Aebersold
D.M.
author
Gautschi
O.
author
Nagel
W.
author
Töpfer
M.
author
Krayenbuehl
J.
author
Ribi
K.
author
Ciernik
L.F.
author
Weder
W.
author
article
2015
Lancet. Oncology
1474-5488
1470-2045
journal
16
16
1651-1658
Aged
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Chemotherapy, Adjuvant
Cisplatin/therapeutic use
Disease Progression
Disease-Free Survival
Europe
Female
Humans
Intention to Treat Analysis
Kaplan-Meier Estimate
Lung Neoplasms/mortality
Lung Neoplasms/pathology
Lymphatic Metastasis
Male
Mesothelioma/mortality
Mesothelioma/pathology
Middle Aged
Neoadjuvant Therapy/adverse effects
Neoadjuvant Therapy/mortality
Neoplasm Recurrence, Local
Neoplasm Staging
Pemetrexed/therapeutic use
Pleural Neoplasms/mortality
Pleural Neoplasms/pathology
Pneumonectomy/adverse effects
Pneumonectomy/mortality
Proportional Hazards Models
Radiotherapy Dosage
Radiotherapy, Adjuvant
Risk Factors
Time Factors
Treatment Outcome
eng
60_published
peer-reviewed
Publication types: Clinical Trial, Phase II ; Comparative Study ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish